A reader submitted the following question to firstname.lastname@example.org, the Motley Fool's health care email address for reader questions and comments:
The NBA draft lottery was last night and Cleveland won the first overall pick again. If you were drafting a drug in development for your biotech, what would be your #1 pick?
Health care analysts Michael Douglass and David Williamson both answered. Michael's pick was Merck's (NYSE:MRK) PD-1 inhibitor, immuno-oncology drug MK-3475. MK-3475 is set to go before the FDA, with its PDUFA date on October 28th for patients with unresectable or metastatic melanoma who have previously been treated with Yervoy. The drug is being tested in combination with therapies from Amgen and Incyte, and Merck is working quickly to get the drug approved for a number of indications.
Watch the video below for more details on why Michael picked MK-3475.
Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson owns shares of Merck. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.